DNA repair status of high-grade serous ovarian cancer change in a treatment course

被引：0
|
作者：
Takaya, Hisamitsu [1 ]
Nakai, Hidekatsu [1 ]
Sakai, Kazuko [2 ]
Nishio, Kazuto [2 ]
Matsumura, Noriomi [1 ]
机构：
[1] Kindai Univ, Dept Obst & Gynecol, Higashiosaka, Osaka, Japan
[2] Kindai Univ, Dept Genome Biol, Higashiosaka, Osaka, Japan
来源：
CANCER SCIENCE | 2022年 / 113卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P7-2-7
引用
收藏
页码：363 / 363
页数：1
相关论文
共 50 条
  • [31] Principles of dormancy evident in high-grade serous ovarian cancer
    Shepherd, Trevor G.
    Dick, Frederick A.
    CELL DIVISION, 2022, 17 (01)
  • [32] Profiles of Genomic Instability in High-Grade Serous Ovarian Cancer Predict Treatment Outcome
    Wang, Zhigang C.
    Birkbak, Nicolai Juul
    Culhane, Aedin C.
    Drapkin, Ronny
    Fatima, Aquila
    Tian, Ruiyang
    Schwede, Matthew
    Alsop, Kathryn
    Daniels, Kathryn E.
    Piao, Huiying
    Liu, Joyce
    Etemadmoghadam, Dariush
    Miron, Alexander
    Salvesen, Helga B.
    Mitchell, Gillian
    DeFazio, Anna
    Quackenbush, John
    Berkowitz, Ross S.
    Iglehart, J. Dirk
    Bowtell, David D. L.
    Matulonis, Ursula A.
    CLINICAL CANCER RESEARCH, 2012, 18 (20) : 5806 - 5815
  • [33] Prexasertib: an investigational checkpoint kinase inhibitor for the treatment of high-grade serous ovarian cancer
    Evangelisti, Giulio
    Barra, Fabio
    Moioli, Melita
    Sala, Paolo
    Stigliani, Sara
    Gustavino, Claudio
    Costantini, Sergio
    Ferrero, Simone
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2020, 29 (08) : 779 - 792
  • [34] Letrozole may be a valuable maintenance treatment in high-grade serous ovarian cancer patients
    Heinzelmann-Schwarz, V.
    Meszaros, A. Knipprath
    Stadlmann, S.
    Jacob, F.
    Schoetzau, A.
    Russell, K.
    Friedlander, M.
    Singer, G.
    Vetter, M.
    GYNECOLOGIC ONCOLOGY, 2018, 148 (01) : 79 - 85
  • [35] CTDNA PROFILING TO PREDICT PROGNOSIS AND OPTIMIZE TREATMENT IN HIGH-GRADE SEROUS OVARIAN CANCER
    Oikkonen, Jaana
    Zhang, Kaiyang
    Salminen, Liina
    Huhtinen, Kaisa
    Schulman, Ingrid
    Andersson, Noora
    Carpen, Olli
    Hietanen, Sakari
    Grenman, Seija
    Lehtonen, Rainer
    Hynninen, Johanna
    Farkkila, Anniina
    Hautaniemi, Sampsa
    CLINICAL CANCER RESEARCH, 2019, 25 (22) : 106 - 106
  • [36] Phylogenetic and signature analyses predict treatment response in high-grade serous ovarian cancer
    Oikkonen, Jaana
    Li, Yilin
    Alkodsi, Amjad
    Carpen, Olli
    Huhtinen, Kaisa
    Hietanen, Sakari
    Grenman, Seija E.
    Lehtonen, Rainer
    Hautaniemi, Sampsa
    CANCER RESEARCH, 2018, 78 (13)
  • [37] Single-cell transcriptomics reveals differential DNA repair signatures after chemotherapy in high-grade serous ovarian cancer
    Farkkila, Anniina
    Zhang, Kaiyang
    Kaipio, Katja
    Lamminen, Tarja
    Lehtonen, Rainer
    Hynninen, Johanna
    Grenman, Seija
    Carpen, Olli
    Hautaniemi, Sampsa
    Vaharautio, Anna
    CANCER RESEARCH, 2017, 77
  • [38] Defining and targeting wild-type BRCA high-grade serous ovarian cancer: DNA repair and cell cycle checkpoints
    Ivy, S. Percy
    Kunos, Charles A.
    Arnaldez, Fernanda I.
    Kohn, Elise C.
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2019, 28 (09) : 771 - 785
  • [39] Improving efficacy of microtubule inhibitors in the treatment of high-grade serous ovarian cancer and ovarian carcinosarcoma.
    Vandenberg, Cassandra J.
    Ho, Gwo-Yaw
    Nesic, Ksenija
    Swisher, Elizabeth M.
    Grimmond, Sean M.
    Wakefield, Matthew J.
    Barker, Holly E.
    Bowtell, David D.
    Scott, Clare L.
    CANCER RESEARCH, 2021, 81 (13)
  • [40] Cell-free circulating tumor DNA methylation in high-grade serous ovarian cancer
    Davis, Kayleigh R.
    Flower, Kirsty J.
    Borley, Jane V.
    Wilhelm-Benartzi, Charlotte S. M.
    Brown, Robert
    CANCER RESEARCH, 2016, 76
12345